Dermatitis
Lebrikizumab demonstrates positive results for face, hand dermatitis at 1 year
Multiple phase 3 studies found that lebrikizumab improved face and hand dermatitis in a majority of patients at 16 weeks and maintained a stable response through 52 weeks, Eli Lilly and Company announced in a press release.
EDP1815 discontinued after failure to reach primary endpoint in atopic dermatitis
Evelo Biosciences has announced that it will cease further development of EDP1815 for atopic dermatitis following its phase 2 study results that showed the primary endpoint was not met, according to a company press release.
Baricitinib ‘potential therapeutic option’ for moderate to severe atopic dermatitis
A 4 mg dose of baricitinib was associated with significant improvement over placebo in a number of efficacy parameters in patients with moderate to severe atopic dermatitis, according to a study.
Upadacitinib exhibits ‘favorable benefit-risk profile’ in atopic dermatitis treatment
Compared with adults, upadacitinib exhibited similar efficacy and safety results in adolescents aged 12 to 17 years in the treatment of moderate to severe atopic dermatitis, according to a study.
Validated IGA for atopic dermatitis strongly correlates with patient-reported outcomes
The validated IGA for atopic dermatitis tool proved to be a reliable and accurate means to assess disease severity and quality of life among adults, adolescents and pediatric patients, according to a study.
FDA to review new drug application for roflumilast foam in seborrheic dermatitis treatment
The FDA has accepted for review a new drug application for roflumilast foam 0.3% for seborrheic dermatitis treatment in patients aged 9 years and older, Arcutis announced in a press release.
Dupilumab improves atopic dermatitis symptoms, quality of life in older adults
Dupilumab was associated with improved clinical, safety and quality of life parameters in older patients with moderate to severe atopic dermatitis, according to findings from a post-hoc analysis of four studies.
Dupixent approved in EU for infants, young children with severe atopic dermatitis
The European Commission approved Dupixent in the European Union for the treatment of severe atopic dermatitis in infants and young children who are candidates for systemic therapy, Sanofi and Regeneron announced in a press release.
VIDEO: Alphyn Biologics’ atopic dermatitis candidate shows positive early results
NEW ORLEANS — In this Healio video exclusive from the American Academy of Dermatology Annual Meeting, Neal Koller, founder and CEO of Alphyn Biologics, discusses the clinical-stage company’s drug pipeline.
Dupilumab improves hand, foot atopic dermatitis in phase 3 study
NEW ORLEANS — Patients with hand and foot atopic dermatitis experienced significant improvement with dupilumab, which sustained an acceptable safety profile, according to phase 3 study results presented here.